Jade Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JBIO research report →
Range $45 – $55
Price Chart
About the company
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
- CEO
- Tom Frohlich
- IPO
- 2021
- Employees
- 55
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on JBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $875.96M
- P/E
- -5.23
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 2.00
- EV/EBITDA
- -4.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -49.11%
- ROIC
- -37.39%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-113,542,000
- Net Income
- $-127,410,000-83.0%
- EPS
- $-4.06+95.2%
- OCF Growth
- -33.0%
- FCF Growth
- -33.3%
- 52W High
- $28.00
- 52W Low
- $8.36
- 50D MA
- $18.99
- 200D MA
- $18.28
- Beta
- 1.45
- RSI (14)
- 34
- Avg Volume
- 904.61K
No earnings-call transcripts are available for JBIO yet.
- Free Float
- 85.6%
- Shares Outstanding
- 60.86M
- Float Shares
- 52.12M
of shares held by institutions
158 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 9.13M | ▲ 2.04M |
| Jupiter Topco LLC | 6.27M | ▲ 6.27M |
| Fairmount Funds Management LLC | 4.55M | 0 |
| Ra Capital Management, L.P. | 3.67M | 0 |
| Vr Adviser, LLC | 3.22M | 0 |
| Janus Henderson Group Ltd. | 3.11M | ▲ 3.11M |
| Bellevue Group AG | 3.06M | ▼ 443.51K |
| Paradigm Biocapital Advisors LP | 2.86M | ▲ 2.86M |
| Blackrock, Inc. | 2.80M | ▲ 487.50K |
| Franklin Resources Inc | 2.79M | ▲ 2.79M |
| State Street Corp | 2.34M | ▲ 1.68M |
| Vanguard Capital Management LLC | 2.24M | ▲ 448.12K |
Held by 181 ETFs
Biggest fund positions in JBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Eisner Mark | other | 47,675 |
| Jun 25, 26 | Eisner Mark | other | 0 |
| Jun 9, 26 | CAIN CHRISTOPHER W. | other | 34,843 |
| Jun 9, 26 | DOBMEIER ERIC | other | 34,843 |
| Jun 9, 26 | Klein Lawrence Otto | other | 34,843 |
| Jun 9, 26 | Lavelle Erin | other | 34,843 |
| Jun 9, 26 | Fairmount Funds Management LLC | other | 34,843 |
| Feb 12, 26 | Dahms Bradford D. | other | 226,875 |
| Feb 12, 26 | Dahms Bradford D. | other | 37,813 |
| Feb 12, 26 | Balta Elizabeth | other | 168,750 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JBIO coverage
Recent articles, reports, and earnings notes.
No research on JBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JBIO report →Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
seekingalpha.com · Sep 30
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
globenewswire.com · Sep 30
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
defenseworld.net · Sep 28
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 9
Jade Biosciences to Participate in Upcoming Conferences
globenewswire.com · Sep 1
Jade Biosciences: Duration Is The Real Product
seekingalpha.com · Aug 19
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 10
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
globenewswire.com · Jun 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.